Clinical Trials Logo

Hypercholesterolemia clinical trials

View clinical trials related to Hypercholesterolemia.

Filter by:

NCT ID: NCT03051100 Completed - Clinical trials for Hypercholesterolemia

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Start date: January 19, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.

NCT ID: NCT03038022 Completed - Clinical trials for Heterozygous Familial Hypercholesterolemia

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Start date: February 9, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH).

NCT ID: NCT03018678 Completed - Clinical trials for Hypercholesterolemia, Familial

Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia

Start date: March 2016
Phase:
Study type: Observational

The purpose of this protocol is to identify and screen potential candidates for future enrollment in a gene therapy clinical trial for HoFH.

NCT ID: NCT03001076 Completed - Atherosclerosis Clinical Trials

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Start date: November 29, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.

NCT ID: NCT02991118 Completed - Clinical trials for Hypercholesterolemia

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

CLEAR Wisdom
Start date: November 18, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.

NCT ID: NCT02990637 Completed - Clinical trials for Overweight and Obesity

The Effect of Olive Leaf Extract Administration on Cardiovascular Health

Start date: June 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of daily supplementation of OLECOL for a period of 8 weeks on cardiovascular risk markers.

NCT ID: NCT02989753 Completed - Clinical trials for Hypercholesterolemia

Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia

Lipiback
Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed as a pilot study in order to estimate the effect of VAL070-A and VAL070-B products and their variability on LDL cholesterol and lipid metabolism since these data are still unknown for these products and in this specific population. Collected data will provide more reliable information which may be used to plan a subsequent larger main study.

NCT ID: NCT02988115 Completed - Clinical trials for Hypercholesterolemia

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

CLEAR Serenity
Start date: November 16, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.

NCT ID: NCT02984982 Completed - Clinical trials for Acute Coronary Syndrome

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

ODYSSEY J-IVUS
Start date: November 15, 2016
Phase: Phase 4
Study type: Interventional

Primary Objective: To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in participants who had acute coronary syndrome (ACS) within 4 weeks prior to randomization, with hypercholesterolemia treated with statin. Secondary Objectives: - To compare the efficacy of alirocumab (Praluent®) with SoC on secondary endpoints including absolute change in percent atheroma volume and normalized TAV after 9 months of treatment. - To evaluate the efficacy of alirocumab (Praluent®) on low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, triglycerides, non-high-density lipoprotein cholesterol and lipoprotein (a) after 9 months treatment. - To evaluate the safety of alirocumab (Praluent®) including the occurrence of cardiovascular events (coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) throughout the study.

NCT ID: NCT02979015 Completed - Clinical trials for Hypercholesterolemia

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Start date: November 29, 2016
Phase: Phase 1
Study type: Interventional

Primary Objective: To assess the safety and tolerability of ascending single SC doses of alirocumab in Chinese healthy subjects. Secondary Objectives: - To assess the pharmacokinetic profile of a single SC dose of alirocumab. - To assess the pharmacodynamic effect of a single SC dose of alirocumab on low-density lipoprotein cholesterol (LDL-C) and other lipid parameters. - To assess the immunogenicity of a single SC dose of alirocumab.